Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$23.65
+0.9%
$21.97
$12.21
$41.31
$694.90M-0.27639,787 shs9,856 shs
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
$88.53
$88.47
$42.00
$89.15
$650.25M0.2461,105 shsN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$2.34
+3.1%
$2.11
$0.98
$3.44
$93.34M0.1732,111 shs1,609 shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$0.31
+1.2%
$0.35
$0.26
$2.83
$38.26M0.792.71 million shs382,564 shs
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
$4.10
$4.10
$1.89
$6.37
$355.05M1.891.16 million shs34.93 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-2.47%+5.63%-1.05%+38.10%-5.25%
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
0.00%0.00%0.00%0.00%0.00%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
+0.89%-3.40%+33.53%+97.39%-7.35%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
+4.93%+2.80%-21.15%+4.00%-83.37%
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.268 of 5 stars
3.41.00.00.02.22.50.6
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
3.6409 of 5 stars
3.51.00.04.11.42.50.0
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.80
Moderate Buy$42.3879.18% Upside
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
0.00
N/AN/AN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
0.00
N/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
3.00
Buy$5.201,588.31% Upside
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BSTC, MRSN, ANAB, BYSI, and PGNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$22.00 ➝ $38.00
6/3/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/29/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$40.00
5/28/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $90.00
5/16/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
5/16/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/15/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$3.00
5/6/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$52.00 ➝ $54.00
5/6/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$4.00 ➝ $3.00
5/1/2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$91.28M7.61N/AN/A$2.33 per share10.15
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
$38.19M17.03$3.38 per share26.18$18.42 per share4.81
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$1.75M53.91N/AN/A($0.37) per share-6.32
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$40.50M0.95N/AN/A($0.08) per share-3.85
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
$34.99M10.15N/AN/A$0.54 per share7.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$145.23M-$4.85N/AN/AN/A-125.70%-282.47%-30.79%8/4/2025 (Estimated)
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
$24.47M$3.3337.5117.60N/A47.43%14.81%14.46%N/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$11.12MN/A0.00N/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$69.19M-$0.59N/AN/AN/A-217.63%-990.16%-48.87%8/12/2025 (Estimated)
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
-$68.55M-$0.80N/AN/AN/A-180.28%-129.46%-53.23%N/A

Latest BSTC, MRSN, ANAB, BYSI, and PGNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.47N/AN/AN/A$11.55 millionN/A
5/15/2025Q1 2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million
5/12/2025Q1 2025
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A-$0.06N/A$0.11N/AN/A
5/5/2025Q1 2025
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
N/AN/AN/AN/AN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/AN/AN/AN/AN/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
8.25
8.25
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
N/A
66.24
66.24
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
2.49
2.49
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/A
1.83
1.83
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.99
2.12
2.12

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
60.34%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
93.92%
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
70.96%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10029.38 million19.54 millionOptionable
BioSpecifics Technologies Corp. stock logo
BSTC
BioSpecifics Technologies
77.35 millionN/ANot Optionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8040.32 million28.50 millionOptionable
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
150124.63 million108.43 millionOptionable
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
7986.60 millionN/AOptionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$23.65 +0.20 (+0.85%)
As of 10:22 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

BioSpecifics Technologies stock logo

BioSpecifics Technologies NASDAQ:BSTC

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$2.34 +0.07 (+3.08%)
As of 10:23 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Mersana Therapeutics stock logo

Mersana Therapeutics NASDAQ:MRSN

$0.31 +0.00 (+1.22%)
As of 10:23 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Progenics Pharmaceuticals stock logo

Progenics Pharmaceuticals NASDAQ:PGNX

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.